(Bloomberg) -- Bayer AG’s kidney drug Kerendia helped patients avoid complications from a common form of heart failure in a ...

Merck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, vindicating a decision by the big US pharma to buy into the project for $1 billion.

Bayer plans to launch Acoramidis, a treatment for a rare heart disease called transthyretin amyloid cardiomyopathy, near the end of the first quarter, as well as elinzanetant, a non-hormonal ...

Bayer acquires rights to Cytokinetics' heart drug in Japan Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug development ...

The drug also cut cardiovascular outcomes – including death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke or hospitalisation for heart failure – by 14%.